OMT-28
- Generic Name
- OMT-28
Omeicos Therapeutics Completes Enrollment in Phase 2a Study of OMT-28 for Primary Mitochondrial Disease
• Omeicos Therapeutics completed enrollment in the phase 2a PMD-OPTION study, evaluating OMT-28 in primary mitochondrial disease (PMD) patients with myopathy and cardiomyopathy.
• The PMD-OPTION study enrolled 28 PMD patients, featuring a 12-week run-in phase followed by a 24-week treatment period with a 24 mg daily dose of OMT-28.
• Primary endpoints of the study include safety, tolerability, and reduction of Growth differentiation factor 15 (GDF-15) levels, with top-line data expected by mid-2025.
• OMT-28, a first-in-class small molecule, aims to improve cell metabolism and mitochondrial function, potentially offering a new treatment option for PMD patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath